About Us

Board Members

Magid Abraham, PhD, CEO and Co-Founder

Dr. Abraham is CEO and co-founder of NeuraWell, a mental health therapeutics company. He co-founded ‘ComScore’, where he focused on innovation and industry leadership, and was CEO of ComScore for 14 years and took it public in 2007. He was founder and CEO of Paragren Technologies, producing CRM systems and president of IRI, a major international research company, which he led through sustained growth and innovation. Dr. Abraham received a Ph.D. and an M.B.A. from MIT, and is Engineer of the École Polytechnique, France. He became a Visiting Scholar at Stanford in 2015, where he taught teaching at the Graduate School of Business for three years. He serves on a number of commercial and institutional boards. He is a world expert on consumer and market measurement and analytics and has authored seminal award-winning articles. He received some of the most prestigious awards in the field, was named EY Entrepreneur of the Year and inducted in the Entrepreneurship Hall of Fame and designated “Technology Pioneer” by the World Economic Forum.

Ken Gillman, MD, Clinical Neuropharmacologist and Co-Founder

Dr Ken Gillman, a ‘Clinical Neuro-pharmacologist’ and a retired clinical psychiatrist. Ken has published many scientific review papers about neuro-pharmacology in prestigious journals. Details are in PubMed, the ‘Publications’ menu, and his ‘Google Scholar’ profile. He is an internationally acknowledged authority on serotonin toxicity. and also an expert on the underused anti-depressants drugs called MAOIs. That requires him to be an expert in drug adverse reactions and interactions involving most drugs that affect the nervous system, but especially: MAOIs, TCAs, SSRIs, and SNRIs.

Tom Insel, MD, Chairman of the Board and Co-Founder

Thomas R. Insel, MD, a psychiatrist and neuroscientist, is a co-founder and President of Mindstrong Health. From 2002-2015, Dr. Insel served as Director of the National Institute of Mental Health (NIMH), the component of the National Institutes of Health (NIH) committed to research on mental disorders. Prior to serving as NIMH Director, Dr. Insel was Professor of Psychiatry at Emory University where he was founding director of the Center for Behavioral Neuroscience in Atlanta. Most recently (2015 – 2017), he led the Mental Health Team at Verily (formerly Google Life Sciences) in South San Francisco, CA. Dr. Insel is a member of the National Academy of Medicine and has received numerous national and international awards including honorary degrees in the U.S. and Europe.